OXiGENE Says Phase 2 Data on ZYBRESTAT May Produce Transient Cut
OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation today of data from a Phase 2 trial of ZYBRESTAT (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), a degenerative eye disease.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.